Deep Sweet Syndrome Secondary to Pegfilgrastim

J Drugs Dermatol. 2022 Apr 1;21(4):422-424. doi: 10.36849/JDD.4794.

Abstract

Sweet syndrome, or acute febrile neutrophilic dermatosis, is a skin condition consisting of erythematous papules and plaques in association with fever, neutrophilia, and a neutrophilic infiltrate that typically involves the papillary dermis. Although development is most commonly idiopathic, medications are also frequently associated with the eruption, notably, the granulocyte colony-stimulating factor (G-CSF), filgrastim. Pegylated G-CSF, despite similar activity, is not commonly reported, with only four published cases. We present a case of drug-induced sweet syndrome with unique histologic features (deep inflammatory infiltrate) in association with the usage of pegfilgrastim in the treatment of invasive ductal carcinoma of the breast. J Drugs Dermatol. 2022;21(4):422-424. doi:10.36849/JDD.4794.

Publication types

  • Case Reports

MeSH terms

  • Filgrastim / adverse effects
  • Granulocyte Colony-Stimulating Factor / adverse effects
  • Humans
  • Polyethylene Glycols / adverse effects
  • Sweet Syndrome* / chemically induced
  • Sweet Syndrome* / diagnosis
  • Sweet Syndrome* / drug therapy

Substances

  • Granulocyte Colony-Stimulating Factor
  • pegfilgrastim
  • Polyethylene Glycols
  • Filgrastim